20 articles
Real-world data shows GLP-1 users had significantly lower odds of foot ulcers, bone infections, and amputations compared to SGLT2 inhibitor users.
Major diabetes trial shows GLP-1 drugs maintain cardiovascular benefits when used alongside SGLT2 inhibitors, supporting combination therapy.
SGLT2 inhibitor dapagliflozin protects diabetic kidneys by raising β-hydroxybutyrate and suppressing iron-driven cell death (ferroptosis).
A large VA study finds SGLT2 inhibitors cut dementia risk by nearly 40% in older adults with depression, bipolar disorder, or schizophrenia.
A comprehensive review of AGIs explains how acarbose and miglitol manage type 2 diabetes while reducing hypoglycemia and lactic acidosis risks.
A landmark RCT of 5,047 type 2 diabetics finds GLP-1 agonists linked to fewer hospitalizations than other second-line therapies.
A comprehensive review maps every oral and injectable non-insulin option for T2DM, from metformin to dual GLP-1/GIP agonists.
A review of 480,000+ adults finds GLP-1 receptor agonist users face rising deficits in vitamin D, iron, calcium, and B vitamins.
Australian expert panel issues landmark 2025 recommendations on managing semaglutide, tirzepatide, and related drugs around surgical and endoscopic procedures.
The dual GLP-1/GIP agonist tirzepatide delivers superior glycemic control and weight reduction, reshaping treatment for type 2 diabetes and obesity.
New data from ASCO shows GLP-1 drugs like semaglutide may dramatically slow cancer progression in colorectal, liver, breast, and lung cancer patients.
A large cohort study finds GLP-1 receptor agonists slash obesity-linked cancer risk by 41%, with tirzepatide outperforming semaglutide dramatically.
Analysis of 2,242 NAFLD clinical trials reveals GLP-1 receptor agonists dominate the pipeline, with semaglutide and liraglutide leading the charge.
Phase III trials show once-weekly CagriSema outperforms placebo on HbA1c and body weight in multiple type 2 diabetes populations.
Two adolescents with T1D and obesity saw major metabolic gains from low-dose semaglutide, cutting insulin needs and improving blood sugar control.
A large real-world study finds GLP-1 drugs semaglutide and tirzepatide dramatically reduce heart failure hospitalization and death in HFpEF patients.
A large EHR analysis finds GLP-1 users face a 48% higher relative risk of sensory disturbances — though absolute increases remain tiny.
Advanced incretin therapies demonstrate benefits for cardiovascular health, fatty liver disease, and cognitive decline beyond glucose control.
New data from 111,000+ women shows GLP-1 agonists cut breast cancer rates by 30%, spurring a major prevention trial.
A roundup of endocrinology breakthroughs: GLP-1s post-surgery, vitamin D cutting diabetes risk, and resistance training protecting 140,000 professionals.
